Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, MO, announced today it has completed the sale of ZymeFlow and its related group of companies to ShawKwei & Partners (ShawKwei), an Asian private equity industrial investor. Terms of the transaction were not disclosed.
Based in Houston, Texas, ZymeFlow’s ecofriendly and patented products and services are highly efficient in the decontamination and maintenance of chemical plants and energy refinery facilities in the US and around the world. ShawKwei purchased ZymeFlow in partnership with management from investors, including TSCP. The acquisition supports ShawKwei’s energy transition investment strategy of a lower carbon economy.
“Our collaboration with ZymeFlow’s leadership team enabled the company to strengthen its management team and enhance its products and services while maintaining the highest level of customer service,” said Harry Holiday, Managing Director at Thompson Street Capital Partners. “ZymeFlow is well positioned for both strategic and geographic expansion and we’re excited to see what the future holds.”
Founded more than 35 years ago, ZymeFlow provides customers with innovative solutions using proprietary advanced chemistries that are biodegradable, environmentally safe, and cost efficient. ZymeFlow owns patented products and engineering application methods including ZymeFlow®, Rezyd-H™, CatZyme RT™, and Vapour-Phase® together with service staff and equipment for the decontamination of process equipment in refineries, chemical plants, and industrial facilities. ZymeFlow products and application services are sold to both onshore and offshore energy and chemical customers in over 55 countries.
“Today there is an urgent need to use the safest and most effective ZymeFlow decontamination products and services that are 100% biodegradable, safe, non-toxic, and incredibly powerful,” said Tom McQuery, Founder and President of ZymeFlow. “ShawKwei is an experienced global investor in the energy transition industry and is committed to growing ZymeFlow in both the US and international markets. The ZymeFlow management team is excited to be part of the ShawKwei group of companies, and in combination with CR3’s capabilities ZymeFlow will be able to expand into an even larger combined customer base.”
